Data Foundry

Drug recalls 2023

Metoprolol Succinate Extended-Release Tablets — Class II drug recall D-0169-2023

Terminated recall by Ascend Laboratories, LLC, reported 2023-02-01, distributed nationwide. Failed Dissolution Specification

Recall numberD-0169-2023
Product typeDrug
ClassificationClass II
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmAscend Laboratories, LLC, Parsippany, NJ, United States
Recall initiated2023-01-05
Classified2023-01-20
Reported by FDA2023-02-01
Terminated2024-08-15
DistributedNationwide (US)
Quantity49,632 bottles
Reason classesspecification failure
NDC67877-0590, 67877-0590-01, 67877-0590-05, 67877-0590-10, 67877-0590-30, 67877-0590-60, 67877-0591, 67877-0591-01, 67877-0591-05, 67877-0591-10, 67877-0591-30, 67877-0591-60, 67877-0592, 67877-0592-01, 67877-0592-05, 67877-0592-10, 67877-0592-30, 67877-0592-60, 67877-0593, 67877-0593-01, 67877-0593-05, 67877-0593-10, 67877-0593-30, 67877-0593-60
Lot numbers21142389, 21143094, 21143095, 21143119, 21143121
Expiration dates2023-03-31

Product

Metoprolol Succinate Extended-Release Tablets, USP 25 mg, Rx Only, 100 Tablets per bottle, Manufactured by: Alkem Laboratories Ltd., Mumbai - 400 013, India, Distributed by: Ascend Laboratories, LLC, Parsippany NJ 07054, NDC 67877-590-01.

Reason for recall

Failed Dissolution Specification

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0169-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.